Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Nutrition & Metabolism
Published in: Nutrition & Metabolism 1/2015

Open Access 01-12-2015 | Research

Identification of residues/sequences in the human riboflavin transporter-2 that is important for function and cell biology

Authors: Veedamali S Subramanian, Rubina Kapadia, Abhisek Ghosal, Hamid M Said

Published in: Nutrition & Metabolism | Issue 1/2015

Login to get access

Abstract

Background

Riboflavin (RF) is essential for normal cellular metabolic activities. Human cells obtain RF from their surroundings via a carrier-mediated process that involves RF transporters -1, -2 & -3 (hRFVT -1, -2 & -3; products of SLC52A1, -A2 and -A3 genes, respectively). Little is known about the structural features of these transporters that are important for their function/cell biology. Our aim in this study was to address these issues for the hRFVT-2, a transporter linked to the neurodegenerative disorder Brown-Vialetto-Van Laere Syndrome (BVVLS).

Methods

We used comparative protein-structure modelling to predict residues that interact with two amino acids known to be critical for hRFVT-2 function (the clinical mutants L123 and L339), site-directed mutagenesis, and truncation approach in the human-derived brain U87 cell model.

Results

First we showed that the defect in the function of the L123 and L339 hRFVT-2 clinical mutants is related to a reduction in protein stability/translation efficiency and to retention of the protein in the ER. Mutating V120 and L121 (residues predicted to interact with L123) and L342 (a residue predicted to interact with L339) also led to a significant inhibition in hRFVT-2 function (with no change in membrane expression); this inhibition was associated with changes in protein stability/translation efficiency (in the case of V120A and L342A) and an impairment in transport function (in the case of L121). Truncating the N- and C- terminals of hRFVT-2 led to significant inhibition in RF uptake, which was associated with changes in protein stability/translation efficiency (it was also associated with a partial impairment in membrane targeting in the case of the N-terminal truncation).

Conclusion

These investigations report on identification of residues/sequences in the hRFVT-2 protein that is important for its physiological function and cell biology.
Literature
1.
Cooperman JM, Lopez R. Riboflavin. In: Machlin LJ, editor. Handbook of vitamins: Nutritional, Biochemical and Clinical Aspects. New York: Dekker; 1984. p. 299–327.
2.
Lee E-S, Corfe BM, Powers HJ. Riboflavin depletion of intestinal cells in vitro leads to impaired energy generation and enhanced oxidative stress. Eur J Nutr. 2013;52:1513–21.CrossRef
3.
Verdrengh M, Tarkowski A. Riboflavin in innate and acquired immune responses. Inflamm Res. 2005;54:390–3.CrossRef
4.
Sanches SC, Ramalho LNZ, Mendes-Braz M, Terra VA, Cecchini R, Augusto MJ, et al. Riboflavin (vitamin B-2) reduces hepatocellular injury following liver ischaemia and reperfusion in mice. Food Chem Toxicol. 2014;67:65–71.CrossRef
5.
Rosenthal WS, Adham NF, Lopez R, Cooperman JM. Riboflavin deficiency in complicated chronic alcoholism. Am J Clin Nutr. 1973;26:858–60.
6.
Fernandez-Banares F, Abad-Lacruz A, Xiol X, Gine JJ, Dolz C, Cabre E, et al. Vitamin status in patients with inflammatory bowel disease. Am J Gastroenterol. 1989;84:744–8.
7.
Bonjour JP. Vitamins and alcoholism. V Riboflavin, VI Niacin, VII Pantothenic acid, and VIII Biotin. Int J Vitam Nutr Res. 1980;50:425–40.
8.
Kodentsova VM, Vrzhesinskaia OA, Sokol'nikov AA, Kharitonchik LA, Spirichev VB. Metabolism of B group vitamins in patients with insulin-dependent and non-insulin dependent forms of diabetes mellitus. Vopr Med Khim. 1993;39:26–9.
9.
Pinto JT, Rivlin RS. Drugs that promote renal excretion of Riboflavin. Drug-Nutr Interaction. 1987;5:143–51.
10.
Green P, Wiseman M, Crow YJ, Houlden H, Riphagen S, Lin JP, et al. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am J Hum Genet. 2010;86:485–9.CrossRef
11.
Ciccolella M, Corti S, Catteruccia M, Petrini S, Tozie G, Rizza T, et al. Riboflavin transporter 3 involvement in infantile Brown-Vialetto-Van Laere disease: Two novel mutations. J Med Genet. 2013;50:104–7.CrossRef
12.
Bosch AM, Stroek K, Abeling NG, Waterham HR, IJlst L, Wanders RJA. The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: Natural history, genetics, treatment and future perspectives. Orphanet J Rare Dis. 2012;7:83.CrossRef
13.
Haack TB, Makowski C, Yao Y, Graf E, Hempel M, Wieland T, et al. Impaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto-Van Laere syndrome. J Inherit Metab Dis. 2012;35:943–8.CrossRef
14.
Johnson JO, Gibbs JR, Megarbane A, Urtizberea JA, Hernandez DG, Foley AR, et al. Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. Brain. 2012;135:2875–82.CrossRef
15.
Foley AR, Menezes MP, Pandraud A, Gonzalez MA, Al-Odaib A, Abrams AJ, et al. Tretable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain. 2014;137:44–56.CrossRef
16.
Bosch AM, Abeling NG, Ijlst L, Knoester H, Van der Pol WL, Stroomer AE, et al. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. J Inherit Metab Dis. 2011;34:159–64.CrossRef
17.
Anand G, Hasan N, Jayapal S, Huma Z, Ali T, Hull J, et al. Early use of high-dose riboflavin in a case of Brown-Vialetto-Van Laere syndrome. Dev Med Child Neurol. 2012;54:187–9.CrossRef
18.
Yonezawa A, Masuda S, Katsura T, Inui K. Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol. 2008;295:C632–41.CrossRef
19.
Fujimura M, Yamamoto S, Murata T, Yasujima T, Inoue K, Ohta KY, et al. Functional characteristics of the human ortholog of riboflavin transporter 2 and riboflavin-responsive expression of its rat ortholog in the small intestine indicate its involvement in riboflavin absorption. J Nutr. 2010;140:1722–7.CrossRef
20.
Yao Y, Yonezawa A, Yoshimatsu H, Masuda S, Katsura T, Inui K. Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr. 2010;140:1220–6.CrossRef
21.
Yamamoto S, Inoue K, Ohta KY, Fukatsu R, Maeda JY, Yoshida Y, et al. Identification and functional characterization of rat riboflavin transporter 2. J Biochem. 2009;145:437–43.CrossRef
22.
Yonezawa A, Inui K-I. Novel riboflavin transporter family RFVT/SLC52: Identification, nomenclature, functional characterization and genetic disease. Mol Aspects Med. 2013;34:693–701.CrossRef
23.
Subramanian VS, Rapp L, Marchant JS, Said HM. Role of cysteine residues in cell surface expression of the human riboflavin transporter-2 (hRFT2) in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G100–9.CrossRef
24.
Subramanian VS, Marchant JS, Said HM. Molecular determinants dictating cell surface expression of the human sodium-dependent vitamin C transporter-2 in human liver cells. Am J Physio Gastrointest Liver Physiol. 2010;298:G267–74.CrossRef
25.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) Method. Methods. 2001;25:402–8.CrossRef
26.
Bryson K, McGuffin LJ, Marsden RL, Ward JJ, Sodhi JS, Jones DT. Protein structure prediction servers at University College London. Nucleic Acids Res. 2005;33:W36–8.CrossRef
27.
Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35:W407–10.CrossRef
28.
Dang S, Sun L, Huang Y, Lu F, Liu Y, Gong H, et al. Structure of a fucose transporter in an outward-open conformation. Nature. 2010;467:734–8.CrossRef
29.
Unal ES, Zhao R, Chang MH, Fiser A, Romero MF, Goldman ID. The functional roles of the His247 and His 281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1. J Biol Chem. 2009;284:17846–57.CrossRef
30.
Subramanian VS, Subramanya SB, Rapp L, Marchant JS, Ma TY, Said HM. Differential expression of human riboflavin transporters −1, −2, and −3 in polarized epithelia: A key role for hRFT-2 in intestinal riboflavin uptake. Biochim Biophys Acta. 1808;2011:3016–21.
31.
Suzuki T, Fujikura K, Koyama H, Matsuzaki T, Takahashi Y, Takata K. The apical localization of SGLT1 glucose transporter is determined by the short amino acid sequence in its N-terminal domain. Eur J Cell Biol. 2001;80:765–74.CrossRef
32.
Subramanian VS, Marchant JS, Boulware MJ, Said HM. A C-terminal region dictates the apical plasma membrane targeting of the human sodium-dependent vitamin C transporter-1 in polarized epithelia. J Biol Chem. 2004;279:27719–28.CrossRef
33.
Sun AQ, Salkar R, Sachchidanand, Xu S, Zeng L, Zhou MM, et al. A14- amino acid sequence with a ß-turn structure is required for apical membrane sorting of the rat Ileal bile acid transporter. J Biol Chem. 2003;278:4000–9.CrossRef
34.
Marchant JS, Subramanian VS, Parker I, Said HM. Intracellular trafficking and membrane targeting mechanisms of the human reduced folate carrier in mammalian epithelial cells. J Biol Chem. 2002;277:33325–33.CrossRef
35.
Subramanian VS, Marchant JS, Parker I, Said HM. Cell biology of the human thiamine transporter-1 (hTHTR1). J Biol Chem. 2003;278:3976–84.CrossRef
Metadata
Title
Identification of residues/sequences in the human riboflavin transporter-2 that is important for function and cell biology
Authors
Veedamali S Subramanian
Rubina Kapadia
Abhisek Ghosal
Hamid M Said
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2015
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/s12986-015-0008-3

Other articles of this Issue 1/2015

Nutrition & Metabolism 1/2015 Go to the issue

Research

Chlorogenic acid/chromium supplement rescues diet-induced insulin resistance and obesity in mice

Review

Review: Miglitol has potential as a therapeutic drug against obesity

Research

Iron, folate and vitamin B12 status of Ethiopian professional runners

Research

Influence of obesity on vertebral fracture prevalence and vitamin D status in postmenopausal women

Perspective

Consumption of sugar sweetened beverage is associated with incidence of metabolic syndrome in Tehranian children and adolescents

Methodology

Evaluation of a new whole room indirect calorimeter specific for measurement of resting metabolic rate
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits